Sonelokimab

Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis[1][2][3][4].

Product Specifications

CAS Number

[1414386-05-2]

Product Name Alternative

ALX 0761; M 1095

UNSPSC

12352203

Target

Interleukin Related; MMP

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sonelokimab.html

Purity

99.81

Solubility

H2O

Smiles

[Sonelokimab]

Molecular Weight

(40.11 kDa)

References & Citations

[1]Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25 (7) :751-4. |[2]Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289 (14) :4304-4327. |[3]Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977.|[4]Vanheusden K, et al. Pre-clinical proof-of-concept of ALX-0761, a Nanobody® neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model[C]//ARTHRITIS AND RHEUMATISM. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: Wiley-Blackwell, 2013, 65: S543-S543.